VIP

VIP, or vasoactive intestinal peptide, is a genuine endogenous human signaling peptide with broad physiologic relevance. It differs from many entries in this repository because it is first and foremost a native neuropeptide / hormone rather than a proprietary therapeutic analog. Therapeutic interest has persisted for decades in pulmonary, inflammatory, gastrointestinal, and cytoprotective contexts, but native VIP itself is not a mainstream approved drug. Much of the translational story now runs through analogs or formulations such as aviptadil rather than through raw native-peptide use.

Important names include VIP and vasoactive intestinal peptide. Related translational names such as aviptadil should be cross-referenced but not collapsed into the same identity field because they represent therapeutic analog or formulation strategies rather than the endogenous peptide itself. Identity records should therefore distinguish native biology from therapeutic-development derivatives.

3. Sequence and structure

VIP is a 28-amino-acid peptide belonging to the secretin / glucagon family. Public structural records identify it as a native linear peptide hormone with substantial sequence conservation and classic neuroendocrine signaling behavior. It is structurally elegant but pharmacologically challenging because native peptide stability in circulation is poor.

VIP acts mainly through VPAC1 and VPAC2 receptors, driving vasodilatory, bronchodilatory, secretory, anti-inflammatory, and neuroimmune effects. It is one of the more pleiotropic signaling peptides in the repository, with activity across the gut, lung, vasculature, and nervous system. That breadth is therapeutically attractive but also complicates drug development because effects are systemic and short-lived in native form.

Therapeutic and investigational contexts include pulmonary arterial hypertension, inflammatory lung disease, ARDS / COVID-era research through aviptadil, gastrointestinal motility and secretion biology, and broader immune-modulatory hypotheses. None of this should be mistaken for a routine approved native-VIP drug indication. The correct framing is physiologically important peptide with intermittent therapeutic development.

Native VIP is rapidly degraded in circulation, which has historically limited its usefulness as a systemic drug and pushed development toward analogs, inhaled approaches, or other formulation strategies. The key pharmacology message is short native exposure with potent biologic signaling. Repository users should understand that poor stability is one of the main reasons VIP remains more biologically important than clinically routine.

There is strong mechanistic and physiologic rationale, but therapeutic efficacy evidence is mixed and formulation-dependent. Some pulmonary and cytoprotective applications have generated encouraging signals, yet native VIP has not become a standard approved therapy. Aviptadil-related work has kept interest alive, but recent synthesis suggests outcomes remain unsettled rather than conclusively transformative.

Because VIP is strongly vasoactive and secretory, potential adverse-effect concerns include hypotension, flushing, tachycardia, diarrhea, and route-specific tolerability issues. Safety therefore depends heavily on route, formulation, and patient population. The repository should not treat VIP as inherently gentle simply because it is endogenous.

There is no single approved standardized dosing regimen for native VIP as a mainstream therapeutic drug. Development efforts have used intravenous, inhaled, and analog-based strategies depending on the indication. This section should remain descriptive rather than prescriptive unless linked to a specific clinical protocol.

The following dosing information has been compiled from community forums, researcher discussions, and gray-market sources. This information has NOT been verified through peer-reviewed scientific studies or clinical trials. It does NOT constitute medical advice, a prescription, or a recommendation for human use.

This data is presented solely for informational and educational purposes to document what is commonly discussed in research communities. Dosing protocols may be inaccurate, dangerous, or based on anecdotal reports with no scientific validation. Individual responses vary significantly, and unregulated compounds carry inherent risks including contamination, mislabeling, and unknown side effects.

Always consult qualified medical professionals before making any health-related decisions. The repository maintainers assume no liability for the use or misuse of this information.

Researcher-Reported Dosing Protocols

Common Dose Range: 50-200 mcg per dose

Administration Route: Nasal spray or subcutaneous injection

Frequency: 1-4 times daily

Timing: Split doses throughout the day, such as morning and evening.

Schedule / Protocol: Continuous, with dose adjustments as needed.

Dose Escalation: Start with a lower dose and titrate up based on tolerance and response. For nasal administration, it is common to start with 1 spray and increase to 2 sprays four times daily.

Additional Notes: VIP is often used for its anti-inflammatory and immune-modulating properties. The nasal spray is a common route of administration for CIRS (Chronic Inflammatory Response Syndrome).

This researcher-reported dosing information was compiled from unverified community sources and does not represent validated scientific or medical guidance.

The most visible modern trial activity has often involved VIP analogs or formulations such as aviptadil rather than native peptide alone. Pulmonary and ARDS-related development remains the most recognizable translational corridor. Trial interpretation should be indication- and formulation-specific.

Native VIP is not an FDA-approved mainstream therapeutic drug, and no broad global approval status was identified for it as a standard medicine. Therapeutic development remains active mainly through analogs, formulations, and specialized investigational contexts. This should be stated clearly to prevent confusion between endogenous importance and regulatory status.

13. References and source quality

Highest-value sources include PubChem identity records for native VIP, pulmonary and immunologic review literature, and recent systematic or trial-linked publications on aviptadil. Source quality is good for basic biology and moderate for therapeutic efficacy because outcomes remain heterogeneous and route-dependent.

For research purposes VIP can be synthesized as a defined linear peptide, but therapeutic translation depends strongly on formulation because of rapid degradation and systemic vasoactivity. Inhaled or analog-based strategies are especially relevant in pulmonary development. Manufacturing notes should therefore prioritize route and stability considerations, not just sequence identity.

Closest comparisons include PACAP, secretin-family peptides, and aviptadil as the most important translational derivative. In pulmonary-development contexts it may also be compared with novel vasodilatory or anti-inflammatory peptide strategies. Within this repository it should be positioned as a native signaling peptide with partial therapeutic translation.

Version 0.1 starter entry created March 14, 2026. Evidence basis for this draft: structural identity records for VIP, pulmonary and immunologic review literature, and recent aviptadil trial and review sources. Recommended future upgrade: add a separate linked entry for aviptadil if desired.